{
    "clinical_study": {
        "@rank": "84092", 
        "arm_group": {
            "arm_group_label": "Inborn errors of liver metabolism"
        }, 
        "biospec_descr": {
            "textblock": "Blood samples"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the long-term safety follow-up of patients having\n      treated with HepaStem."
        }, 
        "brief_title": "A Long-term Safety Follow-up Study of Patients Having Received Infusions of HepaStem", 
        "completion_date": {
            "#text": "March 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Urea Cycle Disorders,", 
            "Crigler Najjar Syndrome"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Crigler-Najjar Syndrome", 
                "Urea Cycle Disorders, Inborn", 
                "Cardiomyopathies"
            ]
        }, 
        "detailed_description": {
            "textblock": "The primary objective of the SAF001 study is the long-term safety surveillance of the\n      patients post infusion with HepaStem. Furthermore, the evolution of both the metabolic\n      condition and the quality of life are followed. As much as possible, the surveillance will\n      mimic the standard follow-up of the respective diseases (standard of care). The surveillance\n      will end when the patient is undergoing an organ transplant or takes part in another\n      research study. This surveillance will last up to a maximum of 48 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  All patients having received infusions of HepaStem during a former interventional\n             clinical study conducted by PB and who have terminated their participation in that\n             study.\n\n          -  For subjects under 18 years of age (16 year in UK) and for adult subjects legally\n             incapable: the subject (if capable of signing) and parents or legal representative\n             have provided a written informed assent/consent before enrolment or For an adult\n             subject legally capable: the subject has provided a written informed consent before\n             enrolment.\n\n        Exclusion Criteria:\n\n          -  Subject has received mature liver cells, stem cells transplantation other than\n             HepaStem, or organ liver transplant."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "23 Years", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "The SAF001 study will include all patients having received infusions of HepaStem in any\n        former interventional study conducted by PB."
            }
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 29, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02051049", 
            "org_study_id": "SAF001"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "CN", 
            "UCD"
        ], 
        "lastchanged_date": "January 30, 2014", 
        "location": {
            "contact": {
                "email": "beatrice.devos@promethera.com", 
                "last_name": "B\u00e9atrice De Vos, MD, PhD", 
                "phone": "+32 10 39 43 07"
            }, 
            "contact_backup": {
                "email": "joelle.thonnard@promethera.com", 
                "last_name": "Joelle Thonnard, MD", 
                "phone": "+32 10 39 43 16"
            }, 
            "facility": {
                "address": {
                    "city": "Mont-Saint-Guibert", 
                    "country": "Belgium", 
                    "zip": "1435"
                }, 
                "name": "Promethera Biosciences"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_groups": "1", 
        "official_title": "SAF 001: A Long-term Safety Follow-up Study of Patients Having Received Infusions of HepaStem", 
        "overall_contact": {
            "email": "beatrice.devos@promethera.com", 
            "last_name": "B\u00e9atrice De Vos, MD, PhD", 
            "phone": "32 10 39 43 07"
        }, 
        "overall_contact_backup": {
            "email": "joelle.thonnard@promethera.com", 
            "last_name": "Jo\u00eblle Thonnard, MD", 
            "phone": "32 10 39 43 16"
        }, 
        "overall_official": [
            {
                "affiliation": "Cliniques universitaires Saint-Luc (Belgium)", 
                "last_name": "Fran\u00e7oise Smets, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "CHRU de Lille - Hopital Jeanne de Flandre (France)", 
                "last_name": "Dries Dobbelaere, MD/Prof", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hospital Pedi\u00e1trico de Coimbra (Portugal)", 
                "last_name": "Isabel Gon\u00e7alves, MD/Prof", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Belgium: Federal Agency for Medicines and Health Products, FAMHP", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "Portugal: Autoridade Nacional do Medicamento e Produtos de Saude I.P (Infarmed)", 
                "Israel: Ministry of Health"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Assessment of safety will be achieved by evaluating the following parameters\nPhysical examination\nVital signs\nLaboratory tests\nLiver tumor markers\nAutoimmune markers related to liver pathology\nAnti-HLA antibodies specific for donor cell haplotypes\nMorphology of liver, bile ducts, and portal system by ultrasound\nMorphology of the kidneys by ultrasound\nNon-serious or serious Adverse Events of Special Interest (AESIs) and Serious Adverse Events (SAEs) related to HepaStem therapy.", 
            "measure": "Characterisation of the long term safety profile of HepaStem therapy.", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 4 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02051049"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "This assessment will be based on the evaluation of:\nReport on cognitive skills, behaviour, and health-related quality of life indicators\nNon-serious or serious Adverse Events of Special Interest (AESIs) and Serious Adverse Events (SAEs) related to concomitant medications or other causes\nIndication I: Crigler-Najjar syndrome\nFrequency and severity of metabolic decompensation reported as AESI\nMetabolic parameters\nReport on supportive treatment and any adjustment of:\nPhototherapy\nMedication (eg phenobarbital treatment)\nIndications II: Urea cycle disorders\nFrequency and severity of metabolic decompensation reported as AESI\nMetabolic parameters\nReport on supportive treatment and any adjustment of:\ndiet (natural protein intake, total protein intake, amino acid supplements)\nMedication (eg nitrogen scavengers)", 
            "measure": "To characterize the disease evolution after having received HepaStem therapy and to report on general safety.", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 4 years"
        }, 
        "source": "Promethera Biosciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Promethera Biosciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "January 2014"
    }
}